Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): A multicentre phase IIb randomised active-controlled clinical trial

Sobha Sivaprasad*, A. Toby Prevost, James Bainbridge, Rhiannon Tudor Edwards, David Hopkins, Joanna Kelly, Phil Luthert, Caroline Murphy, Jayashree Ramu, Negin Sarafraz-Shekary, Joana Vasconcelos, Beverley White-Alao, Philip Hykin

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)
183 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): A multicentre phase IIb randomised active-controlled clinical trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science